Zacks Rating on Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY) : 13 analysts are covering Eli Lilly and Company (LLY) and their average rating on the stock is 1.77, which is read as a Buy. 9 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Eli Lilly and Company (LLY) : The most positive equity analysts on Eli Lilly and Company (LLY) expects the shares to touch $116, whereas, the least positive believes that the stock will trade at $55 in the short term. The company is covered by 11 Wall Street Brokerage Firms. The average price target for shares are $95.73 with an expected fluctuation of $17.14 from the mean.


Eli Lilly and Company has lost 0.34% in the last five trading days and dropped 2.32% in the last 4 weeks. Eli Lilly and Company is up 6.78% in the last 3-month period. Year-to-Date the stock performance stands at -3.66%. Eli Lilly and Company (NYSE:LLY): stock turned positive on Tuesday. Though the stock opened at $79.68, the bulls momentum made the stock top out at $79.97 level for the day. The stock recorded a low of $79.445 and closed the trading day at $79.57, in the green by 0.35%. The total traded volume for the day was 3,407,537. The stock had closed at $79.29 in the previous days trading.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.